The novel nucleoside analogue protide nuc-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase i clinical trial

HIGHLIGHTS

• who: Anil Negi from the Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. School of Medicine, University of St Andrews, St. Andrews, United Kingdom. School of Pharmacy and Pharmaceutical Sciences, University of Cardiff, Cardiff, United Kingdom. Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom. Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.